New York, New York–(Newsfile Corp. – October 21, 2020) – The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) alleging that the Company violated federal securities laws.

Class Period: October 15, 2019 and August 7, 2020
Lead Plaintiff Deadline: December 14, 2020

Learn more about your recoverable losses in RETA:
http://www.kleinstocklaw.com/pslra-1/reata-pharmaceuticals-inc-loss-submission-form?id=10370&from=5

The filed complaint alleges that Reata Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Shareholders have until December 14, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

For additional information about the RETA lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66596